中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共3条，第1-3条 帮助

限定条件        
已选(0)清除 条数/页：   排序方式：
Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES) 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2022, 卷号: 17
作者:  Cheng, Y.;  Wu, L.;  Huang, D. Z.;  Wang, Q. M.;  Fan, Y.;  Liu, Z. F.;  Fan, H. J.;  Yao, W. X.;  Liu, B. G.;  Yu, G. H.;  Pan, Y. Y.;  Xu, F.;  He, Z. Y.;  Dong, X. R.;  Ma, R.;  Min, X. H.;  Ge, X. S.;  Chen, H. L.;  Liu, Q.;  Hu, Y. P.;  Liu, Y.;  Song, W. J.;  Yang, C.;  Sun, S. G.
收藏  |  浏览/下载：36/0  |  提交时间：2022/12/23
Trilaciclib  SCLC  Myelopreservation  
Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2022, 卷号: 17
作者:  Wu, Y. -L.;  Zhou, Q.;  Chen, M.;  Pan, Y.;  Jian, O.;  Hu, D.;  Lin, Q.;  Wu, G.;  Cui, J.;  Chang, J.;  Cheng, Y.;  Huang, C.;  Liu, A.;  Yang, N.;  Gong, Y.;  Zhu, C.;  Ma, Z.;  Fang, J.;  Chen, G.;  Zhao, J.;  Shi, A.;  Lin, Y.;  Li, G.;  Liu, Y.;  Wang, D.;  Wu, R.;  Xu, X.;  Shi, J.;  Liu, Z.;  Wang, J.;  Yang, J.
收藏  |  浏览/下载：33/0  |  提交时间：2022/12/23
CCRT  sCRT  PD-L1 inhibitor  
A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2022, 卷号: 17
作者:  Lu, S.;  Zhang, Y.;  Zhang, G.;  Zhou, J.;  Cang, S.;  Cheng, Y.;  Wu, G.;  Cao, P.;  Lv, D.;  Jian, H.;  Chen, C.;  Jin, X.;  Tian, P.;  Wang, K.;  Jiang, G.;  Chen, G.;  Chen, Q.;  Zhao, H.;  Ding, C.;  Guo, R.;  Sun, G.;  Wang, B.;  Jiang, L.;  Liu, Z.;  Fang, J.;  Yang, J.;  Zhuang, W.;  Liu, Y.;  Zhang, J.;  Pan, Y.;  Chen, J.;  Yu, Q.;  Zhao, M.;  Cui, J.;  Li, D.;  Yi, T.;  Yu, Z.;  Yang, Y.;  Zhang, Y.;  Zhi, X.;  Huang, Y.;  Wu, R.;  Chen, L.;  Zang, A.;  Cao, L.;  Li, Q.;  Li, X.;  Song, Y.;  Wang, D.;  Zhang, S.
收藏  |  浏览/下载：42/0  |  提交时间：2022/12/23
third-generation EGFR-TKI  befotertinib  T790M